Loading...
XSTO
CANTA
Market cap29mUSD
Jun 11, Last price  
1.12SEK
1D
8.74%
1Q
-28.21%
Jan 2017
-82.28%
IPO
-86.81%
Name

Cantargia AB

Chart & Performance

D1W1MN
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
16.53%
Rev. gr., 5y
%
Revenues
0k
Net income
-162m
L-42.27%
-3,389,317-3,465,168-7,945,937-8,370,189-17,190,000-44,680,000-60,253,000-91,160,000-110,691,000-173,086,000-366,507,000-362,079,000-280,027,000-161,654,000
CFO
-163m
L-43.23%
-2,915,391-3,779,484-8,262,4866,897,877-30,277,000-39,528,000-41,103,000-104,686,000-111,254,000-156,387,000-346,445,000-358,915,000-286,664,000-162,752,000
Earnings
Aug 26, 2025

Profile

Cantargia AB (publ), a biotechnology company, engages in the research and development of antibody-based treatments for life threatening diseases. The company is developing CAN04, an antibody against Interleukin-1 Receptor Accessory Protein (IL1RAP) to recognize cancer cells and stimulate natural immune system to destroy such cells, as well as block the tumor inflammation that is driven by the Interleukin-1 system and is under phase IIa clinical trial; and CAN10, an antibody against IL1RAP for treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis, and is under preclinical trial. It is also developing CANxx antibodies against IL1RAP. The company has collaboration agreements with Patheon Biologics BV and BioWa Inc. for the manufacture and production of CAN04; and Specialized Medical Services-oncology BV for the clinical study of CAN04. Cantargia AB (publ) was founded in 2010 and is based in Lund, Sweden.
URL
https://cantargia.com/
IPO date
Mar 17, 2015
Employees
24
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
168,468
291,216
383,342
Unusual Expense (Income)
NOPBT
(168,468)
(291,216)
(383,342)
NOPBT Margin
Operating Taxes
(9,735)
Tax Rate
NOPAT
(168,468)
(291,216)
(373,607)
Net income
(161,654)
-42.27%
(280,027)
-22.66%
(362,079)
-1.21%
Dividends
Dividend yield
Proceeds from repurchase of equity
59,281
223,934
BB yield
-9.34%
-56.79%
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
84
119
24
Net debt
(33,036)
(194,747)
(426,668)
Cash flow
Cash from operating activities
(162,752)
(286,664)
(358,915)
CAPEX
(7,089)
Cash from investing activities
55,000
182,095
67,880
Cash from financing activities
(1,066)
54,681
223,934
FCF
(243,220)
(288,666)
(377,904)
Balance
Cash
33,036
194,747
426,668
Long term investments
Excess cash
33,036
194,747
426,668
Stockholders' equity
(1,666,292)
(1,507,788)
(1,233,501)
Invested Capital
1,782,680
1,676,649
1,622,867
ROIC
ROCE
EV
Common stock shares outstanding
183,686
169,771
128,024
Price
1.69
-54.81%
3.74
21.43%
3.08
-83.32%
Market cap
310,429
-51.11%
634,944
61.02%
394,314
-78.68%
EV
277,393
440,197
(32,354)
EBITDA
(165,031)
(287,766)
(379,650)
EV/EBITDA
0.09
Interest
6,372
4
Interest/NOPBT